Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282977685> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4282977685 endingPage "6207" @default.
- W4282977685 startingPage "6207" @default.
- W4282977685 abstract "Abstract Although over 70 protein kinase inhibitors have been approved by FDA since 2001, the protein kinase is still the hot target class of molecularly targeted cancer therapy because of the discovery of new driver kinase fusion mutation and a large number of secondary kinase mutations after the inhibitor treatment in cancer patients with the sequencing technology advancement, the need for new generation specific small molecule kinase inhibitors is still unmet, and it urge the industry to development more accurate, efficient kinase cellular assay models.Ba/F3 line is a popular cell model because many protein kinases and their mutants can transform the Ba/F3 cells to be growth independent of exogenous IL-3 supplement, while their inhibitors can antagonize these effects. Our group have generated a large of cell line panel with over 300 different well validated (sequencing, Western Blot and inhibitor test) Ba/F3 kinase cell lines for kinase inhibitor screening and development, covering several hot kinases, such as EGFR, EML-ALK, FLT3, NTRK, ROS1, HER, BCR-ABL, RET, FGFR1, FGFR2, FGFR3, FGFR4, KRAS, cMET, et al. Except used in in vitro high-throughput compound screening, most of the transformed Ba/F3 lines can grow well in immune-deficient mice and were also used to evaluate the efficacy of drug candidate and its downstream signaling in vivo. Our data indicate that our Ba/F3 cell line panel is a powerful cell model for new kinase inhibitor discovery and development. Citation Format: Yu Wang, Yao Peng, Yao Tang, Lin Zhou, Jinying Ning, Feng Hao. Ba/F3 kinase mutant cell panel, a powerful cell model for the discovery and development of inhibitors for kinase specific mutation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 6207." @default.
- W4282977685 created "2022-06-17" @default.
- W4282977685 creator A5021541475 @default.
- W4282977685 creator A5025623040 @default.
- W4282977685 creator A5040251310 @default.
- W4282977685 creator A5055641788 @default.
- W4282977685 creator A5069852485 @default.
- W4282977685 creator A5079594267 @default.
- W4282977685 date "2022-06-15" @default.
- W4282977685 modified "2023-09-26" @default.
- W4282977685 title "Abstract 6207: Ba/F3 kinase mutant cell panel, a powerful cell model for the discovery and development of inhibitors for kinase specific mutation" @default.
- W4282977685 doi "https://doi.org/10.1158/1538-7445.am2022-6207" @default.
- W4282977685 hasPublicationYear "2022" @default.
- W4282977685 type Work @default.
- W4282977685 citedByCount "0" @default.
- W4282977685 crossrefType "journal-article" @default.
- W4282977685 hasAuthorship W4282977685A5021541475 @default.
- W4282977685 hasAuthorship W4282977685A5025623040 @default.
- W4282977685 hasAuthorship W4282977685A5040251310 @default.
- W4282977685 hasAuthorship W4282977685A5055641788 @default.
- W4282977685 hasAuthorship W4282977685A5069852485 @default.
- W4282977685 hasAuthorship W4282977685A5079594267 @default.
- W4282977685 hasConcept C121608353 @default.
- W4282977685 hasConcept C184235292 @default.
- W4282977685 hasConcept C185592680 @default.
- W4282977685 hasConcept C2781187634 @default.
- W4282977685 hasConcept C502942594 @default.
- W4282977685 hasConcept C51853150 @default.
- W4282977685 hasConcept C526805850 @default.
- W4282977685 hasConcept C54355233 @default.
- W4282977685 hasConcept C55493867 @default.
- W4282977685 hasConcept C62112901 @default.
- W4282977685 hasConcept C82495950 @default.
- W4282977685 hasConcept C86803240 @default.
- W4282977685 hasConcept C95444343 @default.
- W4282977685 hasConcept C97029542 @default.
- W4282977685 hasConceptScore W4282977685C121608353 @default.
- W4282977685 hasConceptScore W4282977685C184235292 @default.
- W4282977685 hasConceptScore W4282977685C185592680 @default.
- W4282977685 hasConceptScore W4282977685C2781187634 @default.
- W4282977685 hasConceptScore W4282977685C502942594 @default.
- W4282977685 hasConceptScore W4282977685C51853150 @default.
- W4282977685 hasConceptScore W4282977685C526805850 @default.
- W4282977685 hasConceptScore W4282977685C54355233 @default.
- W4282977685 hasConceptScore W4282977685C55493867 @default.
- W4282977685 hasConceptScore W4282977685C62112901 @default.
- W4282977685 hasConceptScore W4282977685C82495950 @default.
- W4282977685 hasConceptScore W4282977685C86803240 @default.
- W4282977685 hasConceptScore W4282977685C95444343 @default.
- W4282977685 hasConceptScore W4282977685C97029542 @default.
- W4282977685 hasIssue "12_Supplement" @default.
- W4282977685 hasLocation W42829776851 @default.
- W4282977685 hasOpenAccess W4282977685 @default.
- W4282977685 hasPrimaryLocation W42829776851 @default.
- W4282977685 hasRelatedWork W1766758424 @default.
- W4282977685 hasRelatedWork W1968163540 @default.
- W4282977685 hasRelatedWork W2031220512 @default.
- W4282977685 hasRelatedWork W2047402931 @default.
- W4282977685 hasRelatedWork W2087433131 @default.
- W4282977685 hasRelatedWork W2093107252 @default.
- W4282977685 hasRelatedWork W2093510595 @default.
- W4282977685 hasRelatedWork W2152762134 @default.
- W4282977685 hasRelatedWork W2803733619 @default.
- W4282977685 hasRelatedWork W4230897605 @default.
- W4282977685 hasVolume "82" @default.
- W4282977685 isParatext "false" @default.
- W4282977685 isRetracted "false" @default.
- W4282977685 workType "article" @default.